Quarterly report pursuant to Section 13 or 15(d)

NATURE OF BUSINESS AND ORGANIZATION (Details)

v3.24.3
NATURE OF BUSINESS AND ORGANIZATION (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Sep. 30, 2022
USD ($)
Mar. 31, 2024
USD ($)
segment
Mar. 31, 2023
USD ($)
Dec. 31, 2023
USD ($)
Organization, Consolidation, Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]        
Accumulated deficit   $ (229,403,000)   $ (202,761,017)
Net Income (Loss)   (26,641,983) $ (7,190,470)  
Unrestricted cash and cash equivalents   $ 34,300,000    
Number of reportable segments | segment   1    
Fixed asset impairment charges   $ 0 $ 0  
Uninsured cash balances   39,587,000   9,123,000
Cancer treatment research award through the National Cancer Institute (NCI)        
Organization, Consolidation, Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]        
Government Assistance Amount Cumulative   $ 2,000,000.0    
Government Assistance Transaction Duration   3 years    
Grant received $ 1,980,000 $ 324,000   $ 1,759,000
Minimum        
Organization, Consolidation, Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]        
Property and equipment useful lives   3 years    
Share-based compensation expiration period   12 months    
Maximum        
Organization, Consolidation, Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]        
Property and equipment useful lives   10 years    
Share-based compensation expiration period   3 years    
Leasehold improvements        
Organization, Consolidation, Presentation of Financial Statements Disclosure and Significant Accounting Policies [Line Items]        
Property and equipment useful lives   64 months